Sangamo Therapeutics Q3 revenue falls short, net loss widens

Sangamo Therapeutics

06/11/2025 13:12

Overview

Sangamo Q3 2025 revenue misses analyst expectations, declining significantly from last year

Net loss for Q3 2025 was $34.9 mln, compared to net income last year

Company progresses Fabry disease program, preparing for BLA submission in 2026

Outlook

Sangamo expects BLA submission for Fabry disease in Q1 2026

Company plans CTA submission for prion disease by mid-2026

Sangamo reiterates 2025 operating expenses guidance of $135 mln to $155 mln

Result Drivers

NET LOSS - Consolidated net loss for the third quarter ended September 30, 2025 was $34.9 million, or $0.11 per share, compared to net income of $10.7 million, or $0.04 per share on a fully diluted basis, for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$581,000
$34.40 mln (5 Analysts)
Q3 Net Income
-$34.93 mln
Q3 Adjusted Operating Expenses
$33 mln
Q3 Operating Expenses
$36.10 mln
Q3 Operating Income
-$35.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 72.5% above its November 5 closing price of $0.55

Press Release: ID:nGNX7VN1Wp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)